Study on the Effectiveness of Triamcinolone Hexacetonide Injections for Juvenile Idiopathic Arthritis in Patients Starting TNF Inhibitor Treatment

3 1 1 1

What is this study about?

This clinical trial is focused on studying Juvenile Idiopathic Arthritis (JIA), a condition that causes joint inflammation in children. The trial is investigating the effectiveness of a treatment involving intra-articular glucocorticoid injections, which are injections directly into the joints, in combination with a medication called Tumour Necrosis Factor inhibitor (TNFi). The specific glucocorticoid used in this study is triamcinolone hexacetonide, marketed under the name Lederspan. The purpose of the study is to determine if these joint injections can help more children with JIA achieve a state where their disease is inactive, compared to those who do not receive the injections.

Participants in the study will be randomly assigned to one of two groups. One group will receive the joint injections along with their TNFi treatment, while the other group will receive only the TNFi treatment. The study will be conducted over a period of time, during which the health of the participants will be monitored to see if the joint injections help in maintaining inactive disease without the need for additional glucocorticoid use.

The trial aims to provide valuable information on whether adding joint injections to the standard TNFi treatment can improve outcomes for children with JIA. This could potentially lead to more personalized treatment strategies for managing this condition. The study is designed to ensure that all participants are carefully monitored and assessed by healthcare professionals throughout the trial period.

1 joining the study

Upon joining the study, eligibility is confirmed based on specific criteria, including age between 1-18 years, a diagnosis of juvenile idiopathic arthritis (JIA), and a clinical indication for starting treatment with a type of medication called a tumour necrosis factor inhibitor (TNFi).

Consent is required from participants aged 16 and above, or from guardians for those under 16. Both participants and guardians must consent if the participant is between 16-18 years old.

2 initial assessment

An initial assessment is conducted to evaluate the disease activity using the Juvenile Disease Activity Score (JADAS). This score must be greater than 1, and at least one joint must show active arthritis where an injection is considered.

3 treatment phase

Participants are randomly assigned to receive either intra-articular glucocorticoid injections or no joint injections while starting TNFi treatment. The glucocorticoid used is triamcinolone hexacetonide, administered as a suspension for injection, known as Lederspan.

The objective is to determine if these injections help achieve a sustained inactive disease state compared to those who do not receive the injections.

4 monitoring and follow-up

Participants are monitored over a period to assess the effectiveness of the treatment. The primary goal is to achieve sustained inactive disease without the use of additional glucocorticoids from week 24 to 36.

Secondary assessments include a 30% improvement in the paediatric American College of Rheumatology criteria by week 24.

5 completion of the study

The study is expected to conclude by March 2025. Participants’ progress and outcomes are evaluated to determine the effectiveness of the treatment strategies.

Who Can Join the Study?

Age between 1 and 18 years at the time of signing the informed consent.
Meet the criteria set by the International League of Associations for Rheumatology (ILAR) for non-systemic Juvenile Idiopathic Arthritis (JIA), which is a type of arthritis that affects children.
Need to start Tumour Necrosis Factor (TNF) inhibitor (TNFi) treatment, as agreed upon by at least two doctors. TNFi is a type of medication used to reduce inflammation.
Have not used TNFi before or have used it only once, but stopped at least 3 months before joining the study, and did not have any treatment failure with TNFi.
Have a Juvenile Disease Activity Score (JADAS) greater than 1 at the start of the study and at least one joint with active arthritis where a joint injection is considered. JADAS is a way to measure how active the arthritis is.
Willing to provide written consent to participate in the study. If the participant is 16 or older, they can give consent themselves. If they are younger than 16, their guardians must give consent. If they are between 16 and 18, both the participant and their guardians must give consent.

Who Cannot Join the Study?

Patients who have a different condition than Juvenile Idiopathic Arthritis cannot participate. This condition is a type of arthritis that affects children.
Patients who are not within the age range specified for the study cannot participate. The study is for children aged 2 years and older.
Patients who are not starting treatment with a Tumour Necrosis Factor (TNF) inhibitor cannot participate. TNF inhibitors are medications used to reduce inflammation.
Patients who are unable to receive intra-articular glucocorticoid injections cannot participate. These are injections given directly into the joint to reduce inflammation.
Patients who are not able to follow the study procedures or attend study visits cannot participate.
Patients who have any other medical conditions that might interfere with the study cannot participate.
Patients who are currently participating in another clinical trial cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Oslo Universitetssykehus HF	Oslo	Norway

Other Sites

Site Name	City	Country
Universitetssykehuset Nord-Norge HF	Tromsø	Norway
St. Olavs Hospital HF	Trondheim	Norway
Helse Stavanger HF	Stavanger	Norway
Hcvwr Bowlxc Hp	Bergen	Norway

Trial status

Country	Status	Recruitment Start
Norway	Not recruiting	01.10.2020

Trial locations

Investigated drugs:

Triamcinolone Hexacetonide

Glucocorticoid Injections are used in this trial to treat joints with active arthritis in patients with Juvenile Idiopathic Arthritis (JIA). These injections are given directly into the affected joints to help reduce inflammation and pain. The goal is to see if these injections can help patients achieve a state where their disease is inactive for a longer period.

Tumour Necrosis Factor Inhibitors (TNFi) are medications used to reduce inflammation by blocking a specific protein in the body that causes inflammation. In this trial, patients with JIA are starting treatment with these inhibitors to see if they can help control the disease and improve symptoms.

Investigated diseases:

Juvenile idiopathic arthritis

Juvenile Idiopathic Arthritis – This is a type of arthritis that occurs in children under the age of 16. It is characterized by persistent joint inflammation, which can lead to pain, swelling, and stiffness. The disease can affect one or multiple joints and may also cause symptoms such as fever and rash. Over time, it can lead to joint damage and growth problems if not managed properly. The exact cause is unknown, but it is believed to involve a combination of genetic and environmental factors. The progression of the disease can vary, with some children experiencing symptoms for only a few months, while others may have symptoms for many years.

Trial ID:

2023-510118-21-00

NCT ID:

NCT04614311

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effectiveness of Triamcinolone Hexacetonide Injections for Juvenile Idiopathic Arthritis in Patients Starting TNF Inhibitor Treatment

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?